Closed-Loop Study with Tandem “Artificial Pancreas” Showed Promising Results in Children
A 16-week, multi-center, randomized trial of over 100 children aged 6 to 13 at sites around the U.S. showed improved…
Tandem CCO Brian Hansen Discusses FDA Approval for Control IQ Algorithm with t:slim X2
Last month, the FDA approved the Tandem Diabetes Care update to its t:slim X2 insulin pump Control-IQ technology, clearing the way for the first automated and interoperable insulin dosing system on the U.S. market.
